|Bid||0.0000 x N/A|
|Ask||0.0000 x N/A|
|Day's range||0.0000 - 0.0000|
|Beta (5Y monthly)||2.16|
|PE ratio (TTM)||N/A|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
Scynexis (SCYX) delivered earnings and revenue surprises of 10.71% and 24.67%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Key Insights The considerable ownership by individual investors in SCYNEXIS indicates that they collectively have a...
SCYNEXIS, Inc. ( NASDAQ:SCYX ) is possibly approaching a major achievement in its business, so we would like to shine...
Scynexis (SCYX) enters an exclusive license agreement with GSK to commercialize Brexafemme (ibrexafungerp), an antifungal tablet. GSK will also continue to develop ibrexafungerp for treating invasive candidiasis.
Some of the losses seen by insiders who purchased US$236k worth of SCYNEXIS, Inc. ( NASDAQ:SCYX ) shares over the past...
It's nice to see the SCYNEXIS, Inc. ( NASDAQ:SCYX ) share price up 14% in a week. But that doesn't change the fact that...
SCYNEXIS ( NASDAQ:SCYX ) Third Quarter 2022 Results Key Financial Results Net loss: US$29.6m (loss widened by US$29.0m...
Scynexis (SCYX) delivered earnings and revenue surprises of -21.57% and 17.49%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Scynexis (SCYX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Generally, when a single insider buys stock, it is usually not a big deal. However, when several insiders are buying...
Scynexis (SCYX) delivered earnings and revenue surprises of 7.02% and 12.12%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Some stocks are best avoided. It hits us in the gut when we see fellow investors suffer a loss. Spare a thought for...